{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,29]],"date-time":"2026-09-29T21:25:39Z","timestamp":1790717139536,"version":"4.1.0"},"reference-count":43,"publisher":"Frontiers Media SA","license":[{"start":{"date-parts":[[2023,3,15]],"date-time":"2023-03-15T00:00:00Z","timestamp":1678838400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/100017695","name":"Health Commission of Hunan Province","doi-asserted-by":"publisher","award":["202113012480"],"award-info":[{"award-number":["202113012480"]}],"id":[{"id":"10.13039\/100017695","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Front. Pharmacol."],"abstract":"<jats:p>\n                    <jats:bold>Background:<\/jats:bold>\n                    Pneumocystis jirovecii pneumonia (PJP) has been reported with ICIs but limited to case reports. The clinical features of PJP with ICIs remain mostly unknown. This study aims to investigate the association of PJP with ICIs and describe clinical features.\n                  <\/jats:p>\n                  <jats:p>\n                    <jats:bold>Methods:<\/jats:bold>\n                    Reports of PJP recorded in FAERS (January 2004\u2013December 2022) were identified through the preferred term \u201cPneumocystis jirovecii pneumonia\u201d. Demographic and clinical features were described, and disproportionality signals were assessed through the Reporting Odds Ratio (ROR) and Information Component (IC), using traditional chemotherapy and targeted therapy as comparators, and adjusting signals by excluding contaminant immunosuppressive drugs and pre-existing diseases. A systematic literature review was conducted to describe clinical features of published PJP reports with ICIs. Bradford Hill criteria was adopted for global assessment of the evidence.\n                  <\/jats:p>\n                  <jats:p>\n                    <jats:bold>Results:<\/jats:bold>\n                    We identified 677 reports of PJP associated with ICIs, in which 300 (44.3%) PJP cases with fatal outcome. Nivolumab (IC\n                    <jats:sub>025<\/jats:sub>\n                    2.05), pembrolizumab (IC\n                    <jats:sub>025<\/jats:sub>\n                    1.88), ipilimumab (IC\n                    <jats:sub>025<\/jats:sub>\n                    1.43), atezolizumab (IC\n                    <jats:sub>025<\/jats:sub>\n                    0.36), durvalumab (IC\n                    <jats:sub>025<\/jats:sub>\n                    1.65), nivolumab plus ipilimumab (IC\n                    <jats:sub>025<\/jats:sub>\n                    1.59) have significant signals compared to other drugs in FAERS database. After excluding pre-existing diseases and immunosuppressive agents which may increase susceptibility of PJP, the signals for PJP associated with nivolumab, pembrolizumab, durvalumab, nivolumab plus ipilimumab remained robust (IC\n                    <jats:sub>025<\/jats:sub>\n                    &amp;gt; 0). When compared to other anticancer regimens, although all ICIs showed a lower disproportionate signal for PJP than chemotherapy, nivolumab (IC025 0.33,\n                    <jats:italic>p<\/jats:italic>\n                    &amp;lt; 0.001), pembrolizumab (IC025 0.16,\n                    <jats:italic>p<\/jats:italic>\n                    &amp;lt; 0.001), both PD-1 inhibitors, presented a higher signal for PJP than targeted therapy. Male gender (IC\n                    <jats:sub>025<\/jats:sub>\n                    0.26,\n                    <jats:italic>p<\/jats:italic>\n                    &amp;lt; 0.001) and age &amp;gt;65\u00a0years (IC\n                    <jats:sub>025<\/jats:sub>\n                    0.38,\n                    <jats:italic>p<\/jats:italic>\n                    &amp;lt; 0.001) were predominant in PJP cases associated with across all ICIs. In literature, 15 PJP cases associated with ICIs were reported in 10 published case reports. 12 of 15 (80.0%) of cases received PD-1 inhibitors before PJP was diagnosed.\n                  <\/jats:p>\n                  <jats:p>\n                    <jats:bold>Conclusion:<\/jats:bold>\n                    By the combined analysis of post-marketing data from FAERS and published case reports, we identified ICIs may be associated with PJP, especially in males aged &amp;gt;65years. After accounting for confounders, PD-1 inhibitors emerged with a robust disproportionality signal when compared to PD-L1\/CTLA-4 inhibitors as well as targeted therapy. Further research is warranted to validate our findings.\n                  <\/jats:p>","DOI":"10.3389\/fphar.2023.1129730","type":"journal-article","created":{"date-parts":[[2023,3,15]],"date-time":"2023-03-15T00:27:11Z","timestamp":1678840031000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":29,"title":["Pneumocystis jirovecii pneumonia associated with immune checkpoint inhibitors: A systematic literature review of published case reports and disproportionality analysis based on the FAERS database"],"prefix":"10.3389","volume":"14","author":[{"given":"Shuang","family":"Xia","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hui","family":"Gong","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yi-kun","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ling","family":"Liu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yi-chang","family":"Zhao","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lin","family":"Guo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Bi-kui","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mayur","family":"Sarangdhar","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yoshihiro","family":"Noguchi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Miao","family":"Yan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1965","published-online":{"date-parts":[[2023,3,15]]},"reference":[{"key":"B1","doi-asserted-by":"publisher","first-page":"EC17","DOI":"10.7860\/JCDR\/2016\/19263.7765","article-title":"Absolute lymphocyte count as a surrogate marker of CD4 count in monitoring HIV infected individuals: A prospective study","volume":"10","author":"Agrawal","year":"2016","journal-title":"J. Clin. Diagn Res."},{"key":"B2","doi-asserted-by":"publisher","first-page":"e1040218","DOI":"10.1080\/2162402X.2015.1040218","article-title":"Immunosuppression for ipilimumab-related toxicity can cause pneumocystis pneumonia but spare antitumor immune control","volume":"4","author":"Arriola","year":"2015","journal-title":"Oncoimmunology"},{"key":"B3","doi-asserted-by":"publisher","first-page":"315","DOI":"10.1007\/s002280050466","article-title":"A Bayesian neural network method for adverse drug reaction signal generation","volume":"54","author":"Bate","year":"1998","journal-title":"Eur. J. Clin. Pharmacol."},{"key":"B4","doi-asserted-by":"publisher","first-page":"1603","DOI":"10.1007\/s00277-021-04452-9","article-title":"Primary prophylaxis of bacterial infections and pneumocystis jirovecii pneumonia in patients with hematologic malignancies and solid tumors: 2020 updated guidelines of the infectious diseases working party of the German society of Hematology and medical Oncology (AGIHO\/DGHO)","volume":"100","author":"Classen","year":"2021","journal-title":"Ann. Hematol."},{"key":"B5","doi-asserted-by":"publisher","first-page":"941079","DOI":"10.3389\/fonc.2022.941079","article-title":"Respiratory system toxicity induced by immune checkpoint inhibitors: A real-world study based on the FDA adverse event reporting system database","volume":"12","author":"Cui","year":"2022","journal-title":"Front. Oncol."},{"key":"B6","doi-asserted-by":"publisher","first-page":"225","DOI":"10.1016\/j.therap.2019.01.006","article-title":"Case-non-case studies: Principle, methods, bias and interpretation","volume":"74","author":"Faillie","year":"2019","journal-title":"Therapie"},{"key":"B7","doi-asserted-by":"publisher","first-page":"291","DOI":"10.1186\/s12890-021-01649-6","article-title":"A potential mechanism of the onset of immune-related pneumonitis triggered by anti-PD-1 treatment in a patient with advanced adenocarcinoma lung cancer: Case report","volume":"21","author":"Feng","year":"2021","journal-title":"BMC Pulm. Med."},{"key":"B8","doi-asserted-by":"publisher","first-page":"1000193","DOI":"10.15761\/god.1000193","article-title":"Pneumocystis jirovecii pneumonia in a patient with melanoma treated with infliximab and corticosteroids for ipilimumab-associated colitis","volume":"3","author":"Finbar Slevin","year":"2016","journal-title":"Glob. Dermatol."},{"key":"B9","doi-asserted-by":"publisher","first-page":"6","DOI":"10.1186\/s12916-022-02713-6","article-title":"Interstitial pneumonitis associated with combined regimen of immunotherapy and conventional therapies-pharmacovigilance database analysis with real-world data validation","volume":"21","author":"Guo","year":"2023","journal-title":"BMC Med."},{"key":"B10","doi-asserted-by":"publisher","first-page":"3979","DOI":"10.1016\/j.radcr.2022.07.083","article-title":"Pneumocystis pneumonia in patient with lung adenocarcinoma: Early side effects from pembrolizumab","volume":"17","author":"Hiba","year":"2022","journal-title":"Radiol. Case Rep."},{"key":"B11","doi-asserted-by":"publisher","first-page":"308","DOI":"10.1080\/17843286.2019.1629078","article-title":"Severe pulmonary infections complicating nivolumab treatment for lung cancer: A report of two cases","volume":"75","author":"Inthasot","year":"2020","journal-title":"Acta Clin. Belg"},{"key":"B12","doi-asserted-by":"publisher","first-page":"e14255","DOI":"10.1200\/JCO.2019.37.15_suppl.e14255","article-title":"Absolute lymphocyte count (ALC) as predictor of Pneumocystis Jiroveci Pneumonia (PCP) infection in patients on immune checkpoint inhibitors (ICPi)","volume":"37","author":"Joshi","year":"2019","journal-title":"J. Clin. Oncol."},{"key":"B13","doi-asserted-by":"publisher","first-page":"eabf3861","DOI":"10.1126\/sciimmunol.abf3861","article-title":"PD-1 blockade exacerbates Mycobacterium tuberculosis infection in rhesus macaques","volume":"6","author":"Kauffman","year":"2021","journal-title":"Sci. Immunol."},{"key":"B14","doi-asserted-by":"publisher","first-page":"367","DOI":"10.2165\/00002018-200730050-00001","article-title":"Guidelines for submitting adverse event reports for publication","volume":"30","author":"Kelly","year":"2007","journal-title":"Drug Saf."},{"key":"B15","doi-asserted-by":"publisher","first-page":"2094","DOI":"10.1038\/s41598-019-38618-3","article-title":"Risk factors and clinical characteristics of Pneumocystis jirovecii pneumonia in lung cancer","volume":"9","author":"Lee","year":"2019","journal-title":"Sci. Rep."},{"key":"B16","doi-asserted-by":"publisher","first-page":"389","DOI":"10.1007\/s12094-020-02432-5","article-title":"Cytomegalovirus infection as an underestimated trigger for checkpoint inhibitor-related pneumonitis in lung cancer: A retrospective study","volume":"23","author":"Lin","year":"2021","journal-title":"Clin. Transl. Oncol."},{"key":"B17","doi-asserted-by":"publisher","first-page":"1689","DOI":"10.1111\/1759-7714.13422","article-title":"Opportunistic infections complicating immunotherapy for non-small cell lung cancer","volume":"11","author":"Liu","year":"2020","journal-title":"Thorac. Cancer"},{"key":"B18","doi-asserted-by":"publisher","first-page":"712","DOI":"10.1378\/chest.118.3.712","article-title":"Peripheral blood CD4 + T-lymphocyte counts during Pneumocystis carinii pneumonia in immunocompromised patients without HIV infection","volume":"118","author":"Mansharamani","year":"2000","journal-title":"Chest"},{"key":"B19","doi-asserted-by":"publisher","first-page":"304","DOI":"10.1136\/thoraxjnl-2021-217260","article-title":"Infections due to dysregulated immunity: An emerging complication of cancer immunotherapy","volume":"77","author":"Morelli","year":"2022","journal-title":"Thorax"},{"key":"B20","doi-asserted-by":"publisher","first-page":"297","DOI":"10.1128\/CMR.00013-12","article-title":"Colonization by Pneumocystis jirovecii and its role in disease","volume":"25","author":"Morris","year":"2012","journal-title":"Clin. Microbiol. Rev."},{"key":"B21","doi-asserted-by":"publisher","first-page":"89845","DOI":"10.14744\/ejmo.2020.89845","article-title":"Pneumocystis jiroveci mimicking COVID-19 pneumonia in a patient who is receiving ipilimumab and nivolumab combination therapy: A case report","volume":"2020","author":"Moujaess","year":"2020","journal-title":"Eurasian J. Med. Oncol."},{"key":"B22","doi-asserted-by":"publisher","first-page":"bbab347","DOI":"10.1093\/bib\/bbab347","article-title":"Detection algorithms and attentive points of safety signal using spontaneous reporting systems as a clinical data source","volume":"22","author":"Noguchi","year":"2021","journal-title":"Brief. Bioinform"},{"key":"B23","doi-asserted-by":"publisher","first-page":"327","DOI":"10.1002\/pds.4128","article-title":"Decision making in drug safety-a literature review of criteria used to prioritize newly detected safety issues","volume":"26","author":"Pacurariu","year":"2017","journal-title":"Pharmacoepidemiol Drug Saf."},{"key":"B24","doi-asserted-by":"publisher","first-page":"158","DOI":"10.1056\/NEJMra1703481","article-title":"Immune-related adverse events associated with immune checkpoint blockade","volume":"378","author":"Postow","year":"2018","journal-title":"N. Engl. J. Med."},{"key":"B25","doi-asserted-by":"publisher","first-page":"4610","DOI":"10.3390\/cancers14194610","article-title":"Adrenal insufficiency with anticancer tyrosine kinase inhibitors targeting vascular endothelial growth factor receptor: Analysis of the FDA adverse event reporting system","volume":"14","author":"Raschi","year":"2022","journal-title":"Cancers (Basel)."},{"key":"B26","doi-asserted-by":"publisher","first-page":"449","DOI":"10.1007\/s11523-020-00738-6","article-title":"Lessons to be learnt from real-world studies on immune-related adverse events with checkpoint inhibitors: A clinical perspective from pharmacovigilance","volume":"15","author":"Raschi","year":"2020","journal-title":"Target Oncol."},{"key":"B27","doi-asserted-by":"publisher","first-page":"205","DOI":"10.1007\/s11523-019-00632-w","article-title":"Toxicities with immune checkpoint inhibitors: Emerging priorities from disproportionality analysis of the FDA adverse event reporting system","volume":"14","author":"Raschi","year":"2019","journal-title":"Target Oncol."},{"key":"B28","first-page":"1277676","article-title":"Pneumocystis jiroveci pneumonitis: A rare pneumonia in a patient treated with chemoimmunotherapy","volume":"203","author":"Rath","year":"2021","journal-title":"Am. J. Respir. Crit. Care Med."},{"key":"B29","doi-asserted-by":"publisher","first-page":"519","DOI":"10.1002\/pds.1001","article-title":"The reporting odds ratio and its advantages over the proportional reporting ratio","volume":"13","author":"Rothman","year":"2004","journal-title":"Pharmacoepidemiol Drug Saf."},{"key":"B30","doi-asserted-by":"publisher","first-page":"27","DOI":"10.4103\/JIPO.JIPO_23_19","article-title":"Pneumocystis infection in two patients treated with both immune checkpoint inhibitor and corticoids","volume":"3","author":"Sadek","year":"2020","journal-title":"J. Immunother. Precis. Oncol."},{"key":"B31","first-page":"11","article-title":"A case of pneumocystis jirovecci in a patient with non-small cell lung cancer treated with immunotherapy","volume":"106","author":"Sanka","year":"2023","journal-title":"R I Med. J. (2013)"},{"key":"B32","doi-asserted-by":"publisher","first-page":"697","DOI":"10.1038\/nbt.3623","article-title":"Data mining differential clinical outcomes associated with drug regimens using adverse event reporting data","volume":"34","author":"Sarangdhar","year":"2016","journal-title":"Nat. Biotechnol."},{"key":"B33","doi-asserted-by":"publisher","first-page":"e247","DOI":"10.1016\/j.cllc.2018.12.006","article-title":"Immunosuppression for immune checkpoint-related toxicity can cause pneumocystis jirovecii pneumonia (PJP) in non-small-cell lung cancer (NSCLC): A report of 2 cases","volume":"20","author":"Schwarz","year":"2019","journal-title":"Clin. Lung Cancer"},{"key":"B34","doi-asserted-by":"publisher","first-page":"e163","DOI":"10.1097\/MPH.0000000000001757","article-title":"An usual presentation of pneumocystis jirovecii pneumonia in a woman treated with immune checkpoint inhibitor","volume":"43","author":"Si","year":"2021","journal-title":"J. Pediatr. Hematol. Oncol."},{"key":"B35","doi-asserted-by":"publisher","first-page":"108","DOI":"10.3389\/fimmu.2019.00108","article-title":"Risk of pneumonitis and pneumonia associated with immune checkpoint inhibitors for solid tumors: A systematic review and meta-analysis","volume":"10","author":"Su","year":"2019","journal-title":"Front. Immunol."},{"key":"B36","doi-asserted-by":"publisher","first-page":"1079","DOI":"10.1007\/s00228-020-03083-9","article-title":"Incidence risk of PD-1\/PD-L1-related pneumonia and diarrhea in non-small cell lung cancer (NSCLC) patients: A systematic review and meta-analysis of randomized controlled trials","volume":"77","author":"Tong","year":"2021","journal-title":"Eur. J. Clin. Pharmacol."},{"key":"B37","doi-asserted-by":"publisher","first-page":"4809","DOI":"10.1038\/s41467-020-18396-7","article-title":"Transcriptomic profiling of human cardiac cells predicts protein kinase inhibitor-associated cardiotoxicity","volume":"11","author":"van Hasselt","year":"2020","journal-title":"Nat. Commun."},{"key":"B38","doi-asserted-by":"publisher","first-page":"859","DOI":"10.1007\/s40264-018-0664-0","article-title":"Vitamin B(6) in health supplements and neuropathy: Case series assessment of spontaneously reported cases","volume":"41","author":"van Hunsel","year":"2018","journal-title":"Drug Saf."},{"key":"B39","doi-asserted-by":"publisher","first-page":"1721","DOI":"10.1001\/jamaoncol.2018.3923","article-title":"Fatal toxic effects associated with immune checkpoint inhibitors: A systematic review and meta-analysis","volume":"4","author":"Wang","year":"2018","journal-title":"JAMA Oncol."},{"key":"B40","doi-asserted-by":"publisher","first-page":"57","DOI":"10.1186\/1471-2334-4-57","article-title":"The unmasking of pneumocystis jiroveci pneumonia during reversal of immunosuppression: Case reports and literature review","volume":"4","author":"Wu","year":"2004","journal-title":"BMC Infect. Dis."},{"key":"B41","doi-asserted-by":"publisher","first-page":"100951","DOI":"10.1016\/j.eclinm.2021.100951","article-title":"Stevens-johnson syndrome\/toxic epidermal necrolysis in patients treated with immune checkpoint inhibitors: A safety analysis of clinical trials and FDA pharmacovigilance database","volume":"37","author":"Zhu","year":"2021","journal-title":"EClinicalMedicine"},{"key":"B42","doi-asserted-by":"publisher","first-page":"721","DOI":"10.1136\/thoraxjnl-2021-217575","article-title":"Pulmonary tuberculosis associated with immune checkpoint inhibitors: A pharmacovigilance study","volume":"77","author":"Zhu","year":"2022","journal-title":"Thorax"},{"key":"B43","doi-asserted-by":"publisher","first-page":"109053","DOI":"10.1016\/j.intimp.2022.109053","article-title":"Type 1 diabetes with immune checkpoint inhibitors: A systematic analysis of clinical trials and a pharmacovigilance study of postmarketing data","volume":"110","author":"Zhu","year":"2022","journal-title":"Int. Immunopharmacol."}],"container-title":["Frontiers in Pharmacology"],"original-title":[],"link":[{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fphar.2023.1129730\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,3,15]],"date-time":"2023-03-15T00:27:17Z","timestamp":1678840037000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fphar.2023.1129730\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,3,15]]},"references-count":43,"alternative-id":["10.3389\/fphar.2023.1129730"],"URL":"https:\/\/doi.org\/10.3389\/fphar.2023.1129730","relation":{},"ISSN":["1663-9812"],"issn-type":[{"value":"1663-9812","type":"electronic"}],"subject":[],"published":{"date-parts":[[2023,3,15]]},"article-number":"1129730"}}